Cancer
📧 Sign up to get email alerts when something new happens for Cancer.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-03-21FDA Approved: FULPHILA — Supplemental Application (Biocon Biologics Inc.)
FDA supplemental approval for Fulphila (pegfilgrastim-jmdb) by Biocon Biologics Inc. to update/expand the approved labeling for this biosimi…
-
FDA approval · 2018-12-17FDA Approved: MESNEX — Supplemental Application (Baxter Healthcare Company)
The FDA approved a supplemental application for MESNEX (mesna) from Baxter Healthcare Company. The action relates to the approved use of MES…
-
FDA approval · 2018-11-02FDA Approved: UDENYCA — Original Application (Accord BioPharma, Inc.)
FDA approved UDENYCA (pegfilgrastim-cbqv) as an original biologics license application for reducing the duration of neutropenia in patients …
-
FDA approval · 2018-07-20FDA Approved: NIVESTYM — Original Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved NIVESTYM (filgrastim-aafi) from Pfizer as a biosimilar to filgrastim for reducing duration of neutropenia and infection ris…
-
FDA approval · 2018-06-18FDA Approved: NEUPOGEN — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for NEUPOGEN (filgrastim) from Amgen, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-05-25FDA Approved: ETHYOL — Supplemental Application (Legacy Pharma USA Inc.)
FDA approved a supplemental application for Ethyol (amifostine) submitted by Legacy Pharma USA Inc.
-
FDA approval · 2016-04-11FDA Approved: FLUDEOXYGLUCOSE F18 — Original Application (Kreitchman PET Center)
The FDA approved Fludeoxyglucose F18 through an Original Application filed by Kreitchman PET Center for use as a radiopharmaceutical in PET …
-
FDA approval · 2016-03-03FDA Approved: ZARXIO — Supplemental Application (Sandoz Inc.)
The FDA approved Sandoz's supplemental application for Zarxio (filgrastim-sndz), granting biosimilar approval for the same indications as th…
-
FDA approval · 2016-02-26FDA Approved: FLUDEOXYGLUCOSE F 18 — Supplemental Application (Massachusetts General Hospital)
FDA approved a supplemental application for Fludeoxyglucose F-18 submitted by Massachusetts General Hospital to support its use as a radioph…
-
FDA approval · 2015-11-13FDA Approved: FLUDEOXYGLUCOSE F-18 — Original Application (Cardinal Health 414, LLC)
FDA approved Fluorodeoxyglucose F-18 as a radiopharmaceutical for PET imaging to help identify and evaluate malignant lesions in oncology.
-
FDA approval · 2015-10-30FDA Approved: FLUDEOXYGLUCOSE F18 — Original Application (3D Imaging Drug Design and Development LLC)
FDA approved Fluorodeoxyglucose F18 (FDG F-18) as an original radiopharmaceutical for PET imaging to assess metabolic activity in oncology, …
-
FDA approval · 2015-10-27FDA Approved: FLUDEOXYGLUCOSE F 18 — Original Application (Kettering Medical Center)
FDA approved Fludeoxyglucose F-18 (FDG F-18) under an Original Application by Kettering Medical Center for use as a PET imaging radiopharmac…
-
FDA approval · 2015-09-10FDA Approved: FLUDEOXYGLUCOSE F18 — Supplemental Application (THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH)
FDA approved a supplemental application for Fludeoxyglucose F18, a PET imaging radiotracer, likely updating labeling to reflect current use …
-
FDA approval · 2015-08-31FDA Approved: FLUDEOXYGLUCOSE F 18 — Original Application (SOFIE Co.)
FDA approved the original application for Fludeoxyglucose F-18 (FDG F-18) from SOFIE Co., a radiopharmaceutical used in PET imaging for diag…
-
FDA approval · 2015-08-18FDA Approved: SODIUM FLUORIDE F 18 — Original Application (SOFIE Co.)
FDA approved Sodium Fluoride F-18 from SOFIE Co. via an Original Application for use as a radiopharmaceutical in PET bone imaging to evaluat…
-
FDA approval · 2015-07-17FDA Approved: FLUDEOXYGLUCOSE F18 — Original Application (The Regents of the University of Michigan)
The FDA approved the Original Application for Fludeoxyglucose F-18, a radiopharmaceutical used for PET imaging. The submission was sponsored…
-
FDA approval · 2015-06-23FDA Approved: FLUDEOXYGLUCOSE F 18 — Original Application (Jubilant DraxImage Inc., dba Jubilant Radiopharma)
FDA approved the Original Application for Fludeoxyglucose F-18 (FDG F-18) radiopharmaceutical for PET imaging, establishing its labeling and…
-
FDA approval · 2015-06-23FDA Approved: FLUDEOXYGLUCOSE F 18 — Original Application (The University of Utah DBA Cyclotron Radiochemistry Lab / Huntsman Cancer Institute)
FDA approved the original application for Fludeoxyglucose F-18 as a radiopharmaceutical imaging agent for PET scans, developed by the Univer…
-
FDA approval · 2015-05-01FDA Approved: FLUDEOXYGLUCOSE F 18 — Original Application (Biomedical Research Foundation of Northwest Louisiana)
FDA approved Fluorodeoxyglucose F-18 as a diagnostic radiopharmaceutical for positron emission tomography (PET) imaging under an original ap…
-
FDA approval · 2014-12-23FDA Approved: NEULASTA — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for NEULASTA (pegfilgrastim) filed by Amgen, Inc, allowing changes to the product as described i…
-
FDA approval · 2014-12-18FDA Approved: FLUDEOXYGLUCOSE F-18 — Original Application (Pharmalogic South Carolina, LLC)
FDA approved Fludeoxyglucose F-18 as a radiopharmaceutical imaging agent for PET scans under an Original Application by Pharmalogic South Ca…
-
FDA approval · 2014-09-25FDA Approved: FLUDEOXYGLUCOSE F 18 — Original Application (Massachusetts General Hospital)
The FDA granted original approval for Fluorodeoxyglucose F-18, a radiopharmaceutical from Massachusetts General Hospital, for use with PET i…
-
FDA approval · 2014-04-17FDA Approved: ARANESP — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for ARANESP (darbepoetin alfa) from Amgen.
-
FDA approval · 2014-02-05FDA Approved: FLUDEOXYGLUCOSE F 18 — Original Application (Washington University School of Medicine)
FDA approves the original application for Fludeoxyglucose F-18 (FDG F-18), a radiopharmaceutical used in PET imaging to localize abnormal me…
-
FDA approval · 2014-01-13FDA Approved: FLUDEOXYGLUCOSE F18 — Original Application (The University of Texas MD Anderson Cancer Center)
FDA approved the original application for FLUDEOXYGLUCOSE F18, a PET imaging radiopharmaceutical developed by The University of Texas MD And…